• Expert Alert: Advancing individualized medicine through genomics

a glass board with futuristic computer like images representing (AI) Artificial Intelligence and a person's hands writing on the board

ROCHESTER, Minn. – The virtual 10th Annual Individualizing Medicine Conference on Oct. 8–9 will highlight the latest discoveries, diagnostics, therapeutics and emerging approaches in the field of genomics. Attendees will hear from renowned experts and learn first-hand how individualized medicine is transforming clinical practice, research and education. Highlighted topics will include artificial intelligence, health disparities, precision oncology, microbiome, genomic clinical applications and challenges, and many others.

Taking the virtual center stage will be keynote speakers Gianrico Farrugia, M.D., president and CEO of Mayo Clinic; Deborah Birx, M.D., senior fellow with the George W. Bush Institute; and Joshua Denny, M.D., CEO of the All of Us Research Program with the National Institutes of Health.

Here are some of the featured speakers who will explore the future of machine learning:

Arjun Athreya, Ph.D., and William Bobo, M.D.

Dr. Arjun Athreya, a Mayo Clinic computer scientist, and Dr. William Bobo, M.D., a Mayo Clinic psychiatrist, recently developed a computer algorithm to accurately and efficiently predict whether a patient with depression will respond to an antidepressant. Their research, published in Neuropsychopharmacology, represents a possible step forward in individualizing treatment for major depressive disorder. It also demonstrates collaboration between computer scientists and clinicians using large datasets to address the challenges of individualizing medicine practices of globally devastating diseases.

Liewei Wang, M.D., Ph.D.

Dr. Liewei Wang, a Mayo Clinic pharmacogenomics researcher, is working to identify and understand how biomarkers can predict and contribute to how a person responds to a particular drug, especially drugs used to treat cancer. In one study, she investigates a series of biomarkers related to the initial treatment for patients with estrogen receptor-positive, or ER+, breast cancer with a class of drugs called aromatase inhibitors. In the Breast Cancer Genome-Guided Therapy (BEAUTY) study, she has identified biomarkers for selection and repurposed a class of epigenetic drugs to treat chemotherapy-resistant patients.

Bradley Erickson, M.D., Ph.D.

Dr. Bradley Erickson, M.D., a Mayo Clinic diagnostic radiologist, uses AI to extract information from medical images for diagnostic, prognostic and therapeutic purposes. His research includes developing and validating algorithms that can detect progression and regression or risk of disease and predict molecular markers from medical images. In one recent study, Dr. Bradley used AI tools to rapidly scan MRI images and successfully identify molecular markers for patients with glioma, a type of brain cancer.

Media: To register, please visit Mayo Clinic Center for Individualized Medicine conference and use "MEDIA" as the discount code to receive complimentary registration.

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news. For information on COVID-19, including Mayo Clinic's Coronavirus Map tracking tool, which has 14-day forecasting on COVID-19 trends, visit the Mayo Clinic COVID-19 Resource Center.

MEDIA CONTACT: To schedule an interview with AI experts contact Colette Gallagher, Mayo Clinic Public Affairs, newsbureau@mayo.edu.

Related articles